- Home
- EDTK vs CMMB Comparison
EDTK vs CMMB Comparison
Compare EDTK & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- CMMB
- Stock Information
- Founded
- EDTK 2013
- CMMB 2004
- Country
- EDTK China
- CMMB Israel
- Employees
- EDTK N/A
- CMMB N/A
- Industry
- EDTK Other Consumer Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- CMMB Health Care
- Exchange
- EDTK Nasdaq
- CMMB Nasdaq
- Market Cap
- EDTK 16.7M
- CMMB 13.7M
- IPO Year
- EDTK 2020
- CMMB N/A
- Fundamental
- Price
- EDTK $1.06
- CMMB $2.80
- Analyst Decision
- EDTK
- CMMB Strong Buy
- Analyst Count
- EDTK 0
- CMMB 2
- Target Price
- EDTK N/A
- CMMB $26.50
- AVG Volume (30 Days)
- EDTK 5.3K
- CMMB 252.0K
- Earning Date
- EDTK 08-08-2025
- CMMB 11-12-2025
- Dividend Yield
- EDTK N/A
- CMMB N/A
- EPS Growth
- EDTK N/A
- CMMB N/A
- EPS
- EDTK N/A
- CMMB N/A
- Revenue
- EDTK $893,690.00
- CMMB N/A
- Revenue This Year
- EDTK N/A
- CMMB N/A
- Revenue Next Year
- EDTK N/A
- CMMB N/A
- P/E Ratio
- EDTK N/A
- CMMB N/A
- Revenue Growth
- EDTK N/A
- CMMB N/A
- 52 Week Low
- EDTK $0.80
- CMMB $2.39
- 52 Week High
- EDTK $1.20
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- EDTK 51.12
- CMMB 43.42
- Support Level
- EDTK $0.97
- CMMB $2.95
- Resistance Level
- EDTK $1.07
- CMMB $3.29
- Average True Range (ATR)
- EDTK 0.04
- CMMB 0.27
- MACD
- EDTK 0.00
- CMMB -0.07
- Stochastic Oscillator
- EDTK 61.59
- CMMB 11.54
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.